New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

Hagop M. Kantarjian, Moshe Talpaz, Francis Giles, Susan O'Brien, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality. Identification of the BCR-ABL kinase fusion protein and its central role in the pathogenesis of CML provided new opportunities to develop rational molecular targeted therapies. This review provides an update on the underlying pathophysiologies of disease progression and imatinib mesylate resistance, leading to the development of new targeted tyrosine kinase inhibitors for managing CML. Imatinib, a selective inhibitor of BCR-ABL, represents a major success in the era of target-directed cancer chemotherapy. However, patients with advanced CML have been less sensitive to therapy and responses have been short. In addition, treatment resistance is an emerging problem at all disease stages. Insight into factors involved in imatinib resistance and disease progression has highlighted a role for such BCR-ABL-dependent factors as amplification and overexpression of the BCR-ABL gene and the emergence of mutant isoforms of BCR-ABL. However, BCR-ABL-independent factors, including leukemogenic pathways involving kinases other than BCR-ABL, also play a part. In light of the limitations of imatinib against these factors, newer tyrosine kinase inhibitors, including dasatinib (a multitargeted kinase inhibitor of BCR-ABL and Src family kinases) and nilotinib (AMN107, a selective BCR-ABL inhibitor), may provide promising treatment options for patients with CML.

Original languageEnglish (US)
Pages (from-to)913-923
Number of pages11
JournalAnnals of internal medicine
Volume145
Issue number12
DOIs
StatePublished - Dec 19 2006
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Disease Progression
Phosphotransferases
Molecular Targeted Therapy
src-Family Kinases
Protein Kinases
Protein Isoforms
Therapeutics
Imatinib Mesylate
Drug Therapy
Genes
Neoplasms
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide

ASJC Scopus subject areas

  • Internal Medicine

Cite this

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. / Kantarjian, Hagop M.; Talpaz, Moshe; Giles, Francis; O'Brien, Susan; Cortes, Jorge.

In: Annals of internal medicine, Vol. 145, No. 12, 19.12.2006, p. 913-923.

Research output: Contribution to journalReview article

Kantarjian, Hagop M. ; Talpaz, Moshe ; Giles, Francis ; O'Brien, Susan ; Cortes, Jorge. / New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. In: Annals of internal medicine. 2006 ; Vol. 145, No. 12. pp. 913-923.
@article{e93209eb6cc84872afdc80e5cf33108d,
title = "New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance",
abstract = "Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality. Identification of the BCR-ABL kinase fusion protein and its central role in the pathogenesis of CML provided new opportunities to develop rational molecular targeted therapies. This review provides an update on the underlying pathophysiologies of disease progression and imatinib mesylate resistance, leading to the development of new targeted tyrosine kinase inhibitors for managing CML. Imatinib, a selective inhibitor of BCR-ABL, represents a major success in the era of target-directed cancer chemotherapy. However, patients with advanced CML have been less sensitive to therapy and responses have been short. In addition, treatment resistance is an emerging problem at all disease stages. Insight into factors involved in imatinib resistance and disease progression has highlighted a role for such BCR-ABL-dependent factors as amplification and overexpression of the BCR-ABL gene and the emergence of mutant isoforms of BCR-ABL. However, BCR-ABL-independent factors, including leukemogenic pathways involving kinases other than BCR-ABL, also play a part. In light of the limitations of imatinib against these factors, newer tyrosine kinase inhibitors, including dasatinib (a multitargeted kinase inhibitor of BCR-ABL and Src family kinases) and nilotinib (AMN107, a selective BCR-ABL inhibitor), may provide promising treatment options for patients with CML.",
author = "Kantarjian, {Hagop M.} and Moshe Talpaz and Francis Giles and Susan O'Brien and Jorge Cortes",
year = "2006",
month = "12",
day = "19",
doi = "10.7326/0003-4819-145-12-200612190-00008",
language = "English (US)",
volume = "145",
pages = "913--923",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "12",

}

TY - JOUR

T1 - New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

AU - Kantarjian, Hagop M.

AU - Talpaz, Moshe

AU - Giles, Francis

AU - O'Brien, Susan

AU - Cortes, Jorge

PY - 2006/12/19

Y1 - 2006/12/19

N2 - Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality. Identification of the BCR-ABL kinase fusion protein and its central role in the pathogenesis of CML provided new opportunities to develop rational molecular targeted therapies. This review provides an update on the underlying pathophysiologies of disease progression and imatinib mesylate resistance, leading to the development of new targeted tyrosine kinase inhibitors for managing CML. Imatinib, a selective inhibitor of BCR-ABL, represents a major success in the era of target-directed cancer chemotherapy. However, patients with advanced CML have been less sensitive to therapy and responses have been short. In addition, treatment resistance is an emerging problem at all disease stages. Insight into factors involved in imatinib resistance and disease progression has highlighted a role for such BCR-ABL-dependent factors as amplification and overexpression of the BCR-ABL gene and the emergence of mutant isoforms of BCR-ABL. However, BCR-ABL-independent factors, including leukemogenic pathways involving kinases other than BCR-ABL, also play a part. In light of the limitations of imatinib against these factors, newer tyrosine kinase inhibitors, including dasatinib (a multitargeted kinase inhibitor of BCR-ABL and Src family kinases) and nilotinib (AMN107, a selective BCR-ABL inhibitor), may provide promising treatment options for patients with CML.

AB - Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality. Identification of the BCR-ABL kinase fusion protein and its central role in the pathogenesis of CML provided new opportunities to develop rational molecular targeted therapies. This review provides an update on the underlying pathophysiologies of disease progression and imatinib mesylate resistance, leading to the development of new targeted tyrosine kinase inhibitors for managing CML. Imatinib, a selective inhibitor of BCR-ABL, represents a major success in the era of target-directed cancer chemotherapy. However, patients with advanced CML have been less sensitive to therapy and responses have been short. In addition, treatment resistance is an emerging problem at all disease stages. Insight into factors involved in imatinib resistance and disease progression has highlighted a role for such BCR-ABL-dependent factors as amplification and overexpression of the BCR-ABL gene and the emergence of mutant isoforms of BCR-ABL. However, BCR-ABL-independent factors, including leukemogenic pathways involving kinases other than BCR-ABL, also play a part. In light of the limitations of imatinib against these factors, newer tyrosine kinase inhibitors, including dasatinib (a multitargeted kinase inhibitor of BCR-ABL and Src family kinases) and nilotinib (AMN107, a selective BCR-ABL inhibitor), may provide promising treatment options for patients with CML.

UR - http://www.scopus.com/inward/record.url?scp=33947224197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947224197&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-145-12-200612190-00008

DO - 10.7326/0003-4819-145-12-200612190-00008

M3 - Review article

C2 - 17179059

AN - SCOPUS:33947224197

VL - 145

SP - 913

EP - 923

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 12

ER -